DoMore Diagnostics

👏 👏 👏 Big thanks to Innovation Norway and Level39 for organizing the brilliant London-based Tech Executive Accelerator (#TEA) sessions, covering #communications, #businessgrowth and #partnershipstrategies with #skilledexperts in the field. We will eagerly follow the companies who completed this program and root for their success! 🎉 Innovation Norway in Europe | Wenn ASA | Itera | Mia Health | Mobydo.com | Ventum Dynamics™ | airMont | Pickr.AI | Mobai | Fortifai | DoMore Diagnostics | BUSINESSCLASS.COM | Cardboard

– Disse resultatene føyer seg inn i rekken av økende dokumentasjon fra store kreftsentre som viser at Histotype Px kan tilpasse behandlingsbeslutninger for kolorektal kreft over hele verden, sier administrerende direktør Torbjørn Furuseth i DoMore Diagnostics. Studien, som ble gjennomført i samarbeid med The Ohio State University Comprehensive Cancer Center, viste at løsningen til Domore kan forutsi risiko for kreftspesifikk dødelighet og tilbakefall hos pasienter med tykktarmskreft.

📢 New data indicating predictive properties of Histotype Px® Colorectal 🚨 This study from the leading U.S. cancer center Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute (OSUCCC) was presented at Pathology Visions 2024 this weekend. The data indicates that Histotype Px Colorectal may be used to guide the decision on #chemotherapy after curative surgery in #coloncancer patients. This analysis of 159 patients with stage II and stage III colon cancer at OSUCCC (2016-2020) shows the promising potential of the Histotype Px Colorectal hashtag#biomarker to personalize #adjuvantchemotherapy (ACT). This is a critical decision for one million patients every year, and there is a high medical need to improve patient outcomes. Principal Investigator Dr. Eric Miller, MD, PhD, Department of Pathology, OSUCCC said: “According to current U.S. #clinicalguidelines most high-risk stage II and all stage III colon cancer patients are recommended #ACT, however most patients have a low risk of recurrence and do not benefit from this toxic treatment. The pilot validation data we will present at Pathology Visions 2024 further supports the potential clinical utility of Histotype Px as a tool to guide treatment decisions to escalate or de-escalate ACT treatment. Further research including a larger and more diverse patient cohort and subsequent #clinicalstudies are planned to strengthen these findings and to integrate this promising biomarker in the clinic.” Our CEO and Co-Founder Torbjørn Furuseth is currently present at #PathVisions24 organized by Digital Pathology Association in Orlando. Feel free to connect with him if you want to learn more about Histotype Px and discuss the exciting future of #digitalAIbiomarkers to guide #cancertreatment. Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute will further expand the sample of patients to provide additional support for the #clinicalutility of Histotype Px Colorectal. Stay tuned for more updates and future studies with our partners! Full Press Release and Poster can be found here: https://lnkd.in/dY7uW65m #CancerResearch #Oncology #AIinHealthcare #PrecisionMedicine #ColorectalCancer #DoMore #digitalpathology #precisiononcology #cancer #personalizedmedicine #digitalbiomarkers Giovanni Lujan MD, Vidya Arole, Jessica Maupin, Sandra Boutros, Anne Noonan, Sepp De Raedt, Demond Handley, The Ohio State University Wexner Medical Center

⭐ DoMore Diagnostics is counting down the last few days until #PathVisions24! ⭐ We are excited about the new #clinicaldata on Histotype Px® Colorectal to guide adjuvant therapy in #coloncancer patients that will be presented during Pathology Visions 2024. Our CEO and Co-Founder Torbjørn Furuseth will be attending #PathVisions24, organized by Digital Pathology Association November 3-5 in Orlando. Feel free to connect with him if you want to learn more about Histotype Px and discuss the exciting future of #digitalAI #biomarkers to guide #cancertreatment. #CancerResearch #Oncology #AIinHealthcare #PrecisionMedicine #ColorectalCancer #DoMore #digitalpathology #precisiononcology #cancer #personalizedmedicine

🚨 DoMore Diagnostics announces two new members to our Scientific Advisory Board 🚨 We are proud to welcome Dr. Jeanine Roodhart and Dr. Frank Sinicrope to our Scientific Advisory Board of leading international experts in #colorectalcancer #research and #clinicaloncolocy. Their contributions will be highly valuable for our development and validation of Histotype Px® #digitalbiomarkers towards clinical implementation and better outcomes for #cancerpatients worldwide. John Marshall, Marco Novelli, Takayuki Yoshino, Jakob Nikolas Kather, hans-joachim schmoll, Marc Peeters #digitalpathology #precisionmedicine #precisiononcology #cancer #aiinhealth #colorectalcancer #coloncancer #personalizedmedicine #keyopinionleader #oncology #scientificadvisoryboard Link to full PR: https://lnkd.in/dWZHrCZP

DoMore Diagnostics' CEO and Co-Founder, Torbjørn Furuseth, recently gave an exclusive interview to the DxPx Conference explaining how winning the 42PLUS1 competition has impacted our company, our recent successes with investors and major public grants such as the #EIC Accelerator, as well as explaining how we will bring Histotype Px® Colorectal and pipeline biomarkers to cancer patients worldwide. Read the inspiring interview in the link below. #digitalpathology #aiinhealth #precisionmedicine #precisiononcology #cancer #colorectalcancer #coloncancer #personalizedmedicine  https://lnkd.in/eMgm76iv  

Interesting new publication in #NatureBiotechnology where the #EuropeanInnovationCouncil (EIC) outlines their investment strategy focusing on innovative biomarkers to personalize cancer treatment and DoMore Diagnostics being showcased as one of their main investments. The author describes the #EIC “…as potentially the most effective catalyst of breakthrough science to disruptive innovation, the EIC has the objective of creating an ecosystem that fosters deeptech science-based businesses by harnessing European research and development efforts, unblocking innovative potential in Europe.” #digitalpathology #precisionmedicine #precisiononcology #cancer #aiinhealth #colorectalcancer #coloncancer #personalizedmedicine Link to the article (paid access): https://lnkd.in/dsd5z-6w

🚨 DoMore Diagnostics enters into collaboration with Gustave Roussy, Europe’s leading cancer hospital 🚨 Yet another collaboration with a leading cancer center! Gustave Roussy is ranked as Europe’s #1 cancer centre and #4 globally, and brings together world leading experts across clinical and translational research to bring cutting edge #personalized solutions to patients to improve #cancer care. The study will be led by Dr. Mohamed Amine Bani and aims to validate the performance of Histotype Px® Colorectal on H&E slides and biopsies in a French colorectal cancer patient population. Gustave Roussy is a European powerhouse in developing and implementing cutting-edge innovations to improve cancer treatment, and this collaboration is another major milestone towards validating the potential of and need for Histotype Px as a predictive marker to guide treatment decisions and support inclusion in clinical guidelines. The collaboration also aims to investigate the performance on biopsies and across scanners, which will further broaden the application of Histotype Px. For more information, see full press release: https://lnkd.in/dbXRtmYA #precisionmedicine #aiinhealth #digitalpathology #cancerresearch #colorectalcancer #coloncancer #cancertreatment #predictivebiomarkers #digitalbiomarkers #ai #perseonalizedcancertreatment

New hire 😃 🎉 We are delighted to welcome Madeleine Xuyen Ho to our growing team! Madeleine brings more than twenty years' experience from senior Business Development, Product Strategy and Sales roles in the medical device and digital products industry, most recently from the role of Business and Product Manager at Medistim ASA. Her background includes national and international product and customer lifecycle management. With a strong commercial and end user- focused mindset, Madeleine will play a key role as our new Product Manager in driving DoMore Diagnostics' products to clinical implementation to improve outcomes for cancer patients worldwide.  #aiinhealth #precisionmedicine #cancercare #ai #cancerresearch #colorectalcancer #productmanager https://lnkd.in/eHGHGvE3

DoMore Diagnostics is selected as one of 20 #Nordic Star companies to present at the #NLSDays 2024 pitch competition! ⭐ 🤩 Our CEO and Co-Founder Torbjørn Furuseth will take the stage today at 10:50am, don't miss it! 😀 #AIinhealth #precisionmedicine #cancerresearch #cancer #colorectalcancer #personalizedmedicine